01Indication
Which diagnosis?
Published clinical work mainly concerns confirmed androgenetic alopecia, not hair loss of every cause.
Autologous Microtransplantation · Istanbul
Autologous Microtransplantation · Istanbul
Autologous Micro
Small samples of the patient's own scalp are mechanically disaggregated and the resulting heterogeneous micrograft suspension may be placed into a defined target area. Whole follicular units are not moved, so this is not hair transplantation.
A device or trademark does not prove a known cell composition. Donor site, sample number, processing route, final suspension, delivery layer and clinical endpoint must remain traceable.
Quick Orientation
Four identity questions
The procedure name describes a pathway, not a standard final product.
Comparable clinical use requires the same diagnosis, donor source, processing method, final suspension and measurement approach.
02Collection
Which donor site?
Scalp condition, prior surgery, visible-scar risk and wound healing are assessed.
03Identity
Which final suspension?
Sample size, disaggregation, filtration, carrier and volume define the material.
04Follow-up
Which endpoint?
A fixed measurement zone and comparable imaging are preferred to an immediate visual impression.
What the Method Produces
Autologous scalp tissue · uncultured micrografts
The output is a mixed tissue suspension, not a purified stem-cell dose.
Mechanical fragmentation and filtration can release tissue fragments, extracellular matrix and varied viable or non-viable cellular material. Composition and yield remain process-dependent.
What may be documented
- Use small autologous samples from a defined scalp donor area
- Prepare uncultured micrografts through a traceable mechanical route
- Be considered cautiously as an adjunct for a confirmed diagnosis
- Track donor healing and the hair endpoint as separate outcomes
What cannot be claimed
- Claim a known stem-cell number without validated product analysis
- Move complete follicular units or create a new donor reserve
- Replace hair transplantation or established medical treatment
- Turn laboratory markers into a personal growth guarantee
Characterisation from one research preparation does not define every clinical suspension. Product identity cannot be inferred from a device name.
Medical Suitability
Diagnosis · donor wound · final product · status
Five checks come before tissue collection and scalp delivery.
Personal examination is needed to assess the hair diagnosis, a defensible donor area, the processing plan and the current regulatory setting.
- 01
Confirm the diagnosis
Pattern, activity, miniaturisation, inflammation, scarring and treatable causes are reviewed.
- 02
Assess the donor area
Density, skin condition, earlier scars, healing and cosmetic visibility of punch sites are considered.
- 03
Review procedure risks
Health conditions, medicines, bleeding, infection, allergy and wound healing affect suitability.
- 04
Define the process
Sample number, single-use device, disaggregation, filtration, carrier and final volume are specified.
- 05
Check status and endpoint
Treatment location, product and device status, target layer, measurement method and stopping rule are recorded.
Collection, Processing and Delivery
Donor site · mechanical route · target zone
The tissue chain must stay traceable from punch site to syringe.
Autologous material does not remove contamination, tissue-damage or product-description risks. Time, sterility and material contact all matter.
01Donor
Collect limited scalp samples
Small punch samples are taken from an examined area with an appropriate anaesthetic and wound plan.
- Record site, diameter and number
- Control bleeding and wound closure
- Explain scar and local-thinning risk
02Process
Document mechanical disaggregation
Tissue is processed with traceable single-use equipment and may then be filtered into a carrier.
- Record device, time and steps
- Name carrier, filter and final volume
- Do not infer unmeasured cell content
03Target
Limit local administration
Only the identified suspension is placed into the predefined, measured scalp area.
- Record volume, depth and distribution
- Separate donor and target aftercare
- Set review timing and boundaries
A sterile processing device describes one step. It does not establish composition, clinical effectiveness or regulatory acceptability for a particular use.
Evidence and Limits
Small controlled study · retrospective cohorts
Early signals remain tied to limited and heterogeneous clinical data.
Published work includes a small placebo-controlled half-scalp study and observational cohorts in androgenetic alopecia. Independent replication and product standardisation remain limited.
Recognise small samples
A controlled study involved 27 participants and does not define outcomes for the wider hair-loss population.
Recognise observational limits
Retrospective, single-centre data without a control group cannot establish comparative effectiveness.
Do not merge protocols
One collection and repeated applications are different strategies with different final products.
Keep long-term questions open
Durability, rare harms, product analysis and comparison with established care remain uncertain.
These studies do not establish a general stem-cell treatment or superiority over licensed medicines, observation or hair transplantation.
Individual Decision Plan
No cell package · no automatic repetition
A donor wound needs a defined purpose and an exit rule.
Collection is considered only when diagnosis, donor area, final suspension, alternatives and objective follow-up are clear before the first sample.
Secure the baseline
Record diagnosis, miniaturisation, donor area, imaging, medicines and parallel treatment.
Justify the process
Explain sample number, processing route, final volume, target area and current status.
Limit one decision
Small studies do not create a standard programme or pre-booked repeat procedure.
Reassess the balance
Donor healing, objective hair findings, burden and alternatives determine the next step.
Healing and Follow-Up
Donor wounds · target scalp · hair cycle
Early crusting or swelling does not demonstrate a later hair outcome.
Donor and target areas are reviewed early for safety. A possible hair endpoint needs a later, comparable measurement method.
- 01Early
First days
Tenderness, redness, pinpoint bleeding and swelling may affect donor and target areas.
- 02Healing
Following weeks
Wound closure, infection, visible punch marks, scarring and scalp reaction are assessed.
- 03Endpoint
Following months
Hair count, density or shaft measures are repeated in the same marked area where appropriate.
- 04Decision
Longer-term review
Durability, ongoing miniaturisation, donor burden and established treatment are reconsidered.
Risks and Alternatives
Punch collection · processing · local delivery
Patient-derived tissue is not automatically sterile, scar-free or effective.
Consent includes donor wounds, contamination or product variation, target-area reactions and the possibility of no useful clinical change.
01Collection
Donor site
Pain, bleeding, crusting, infection, delayed healing, visible point scars or local thinning are possible.
02Delivery
Suspension and target
Contamination, tissue damage, swelling, bruising, infection, nodules or persistent inflammation may occur.
03Decision
Alternative priority
Cause-directed care, licensed medicine, observation or hair transplantation may be more appropriate.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Increasing or unexpected symptoms at either site require timely in-person medical assessment and documented review of the procedure.
Istanbul and Follow-Up
Travel around donor healing and later measurement
Autologous microtransplantation does not end with scalp delivery.
Travel planning connects diagnosis, possible collection, documented processing, early wound review and later objective assessment.
01Before travel
Organise existing information
Previous scalp procedures, healing history and current treatment help frame the examination.
02Bağdat Caddesi
Examine donor and target
Diagnosis, scars, donor visibility, alternatives, process and measurement plan are reviewed.
03Procedure
Limit and document
If suitable, collection, processing, delivery and early findings are recorded in one tissue chain.
04After return
Protect later comparison
Wound care, warning signs, local assessment access and review timing are agreed.
The Doctor Aslan Approach
Product clarity before cell claims
Donor site, process, final suspension and endpoint matter more than the device name.
A responsible decision may be not to collect tissue. The plan requires a confirmed diagnosis, a defensible donor wound, a traceable suspension and objective follow-up.
Diagnosis before biopsy
The scalp and hair-loss pattern are examined before donor or target zones are selected.
Keep the tissue chain visible
Punch sites, sample number, processing, final volume, target layer and aftercare are documented.
Limit cell terminology
A mixed micrograft suspension is not described as a purified or dosed stem-cell product.
Keep evidence narrow
Androgenetic alopecia data are not applied to other diagnoses, and repetition is never automatic.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about autologous microtransplantation; no personal diagnosis or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Autologous Microtransplantation?+
Autologous Microtransplantation is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Autologous Microtransplantation?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Assess the donor site · identify the suspension